[1] WHO, UNAIDS. AIDS epidemic update (UNAIDS/09.36E/JC1700E, November 2009. http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/jc1700_epi_update_2009_en.pdf.http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/jc1700_epi_update_2009_en.pdf
[2] UNAIDS. UNAIDS data 2020. https://www.unaids.org/en/resources/documents/2020/unaids-data. [2020-11-17].https://www.unaids.org/en/resources/documents/2020/unaids-data
[3] Shao Y, Liu Y, Xu J, Li T, Liu Y, Hao Y, et al. AIDS vaccine research, from basic research to clinical study. Selected presentations from the clinical and translational 2011 sino-american symposium: 44. The Science/AAAS Custom Publishing Office. 2011.
[4] Su L, Graf M, Zhang Y, von Briesen H, Xing H, Köstler J, et al. Characterization of a virtually full-length human immunodeficiency virus type 1 genome of a prevalent intersubtype (C/B’) recombinant strain in China. J Virol 2000;74(23):13367 − 76. http://dx.doi.org/10.1128/jvi.74.23.11367-11376.2000CrossRef
[5] Teng T, Shao Y. Scientific approaches to AIDS prevention and control in China. Adv Dent Res 2011;23(1):10 − 2. http://dx.doi.org/10.1177/0022034511398871CrossRef
[6] Liang H, He X, Shen RX, Shen T, Tong X, Ma Y, et al. Combined amino acid mutations occurring in the envelope closely correlate with pathogenicity of EIAV. Arch Virol 2006;151(7):1387 − 403. http://dx.doi.org/10.1007/s00705-005-0718-3CrossRef
[7] Shen T, Liang H, Tong X, Fan XJ, He X, Ma Y, et al. Amino acid mutations of the infectious clone from Chinese EIAV attenuated vaccine resulted in reversion of virulence. Vaccine 2006;24(6):738 − 49. http://dx.doi.org/10.1016/j.vaccine.2005.08.084CrossRef
[8] Li HG, Zhang XY, Fan XJ, Shen T, Tong X, Shen RX, et al. A conservative domain shared by HIV gp120 and EIAV gp90: implications for HIV vaccine design. AIDS Res Hum Retroviruses 2005;21(12):1057 − 9. http://dx.doi.org/10.1089/aid.2005.21.1057CrossRef
[9] Douglas HS, Peggy WD, Misrach M, Sara O’Rourke, Faruk S, Terri W, et al. Comparative immunogenicity of HIV-1 clade C envelope proteins for prime/boost studies. PLoS One 2010;5(8):e12076. http://dx.doi.org/10.1371/journal.pone.0012076CrossRef
[10] Zhao K, Zhang Y, Li H. Smallpox vaccine. Medical Biology Product. People’s Medical Publishing House 2007;Chapter 52:963 − 9.
[11] Meng QL, Lin YZ, Ma J, Ma Y, Zhao LP, Li SW, et al. A pilot study on an attenuated Chinese EIAV vaccine inducing broadly neutralizing antibodies. Arch Virol 2011;156(8):1455 − 62. http://dx.doi.org/10.1007/s00705-011-0992-1CrossRef
[12] Liu LX, Wan YM, Wu L, Sun JP, Li HG, Shao YM, et al. Broader HIV-1 neutralizing antibody responses induced by envelope glycoprotein mutants based on the EIAV attenuated vaccine. Retrovirology 2010;Sep 1(7):71. http://dx.doi.org/10.1186/1742-4690-7-71CrossRef
[13] Liu Y, Wu L, Chen JP, Zhou KP, Lu RJ, Hong KX, et al. Construction and immune potency of recombinant vaccinia virus expressing polyvalent HIV antigens. Chin J Virol 2003;3:205 − 9. http://qikan.cqvip.com/Qikan/Article/Detail?id=8414206. (In Chinese). Chin J Virol http://qikan.cqvip.com/Qikan/Article/Detail?id=8414206
[14] Dai KF, Liu Y, Liu MJ, Xu JQ, Huang W, Huang XG, et al. Pathogenicity and immunogenicity of recombinant Tiantan Vaccinia Virus with deleted C12L and A53R genes. Vaccine 2008;26(39):5062 − 71. http://dx.doi.org/10.1016/j.vaccine.2008.06.011CrossRef
[15] Liu Q, Li Y, Luo Z, Yang G, Liu Y, Liu Y, et al. HIV-1 vaccines based on replication-competent Tiantan vaccinia protected Chinese rhesus macaques from simian HIV infection. AIDS 2015;29(6):649 − 58. http://dx.doi.org/10.1097/QAD.0000000000000595CrossRef
[16] Shao Y, Li T, Wolf H, Liu Y, Liu Y, Wang H, et al. P14-15 LB. The safety and immunogenicity of HIV-1 vaccines based on DNA and replication competent vaccinia vector in phase I clinical trial. Retrovirology 2009;6(Suppl 3):404. https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-6-S3-P404.https://retrovirology.biomedcentral.com/articles/10.1186/1742-4690-6-S3-P404
[17] Stephen J Kent, David A Cooper, Mean Chhi Vun, Shao YM, Zhang LQ, Nirmal Ganguly, et al. AIDS vaccine for Asia Network (AVAN): expanding the regional role in developing HIV vaccines. PLoS Med 2010;7(9):e1000331. http://dx.doi.org/10.1371/journal.pmed.1000331CrossRef